Total Adiponectin Is Inversely Associated with Platelet Activation and CHA₂DS₂-VASc Score in Anticoagulated Patients with Atrial Fibrillation

Table 1

Baseline characteristics.

Anthropometric and metabolic data
Age (years)	72.9±8.7
Female gender (%)	41.6
Body mass index (kg/m^2)	27.0±4.3
CHA2DS2-VASc score^#	3 (2–4)
Adiponectin^# (ng/mL)	5.6 (3.2–8.6)
sCD40L^# (ng/mL)	49 (40–70)
Cardiovascular risk factors
Hypertension (%)	88.3
Diabetes mellitus (%)	17.9
Heart failure (%)	16.7
History of stroke/TIA (%)	14.0
History of MI (%)	23.0
Metabolic syndrome (%)	51.0
Concomitant therapies
(i) Antiplatelets (%)	11.3
(ii) ACE inhibitor/ARBs (%)	68.1
(iii) 𝛽 blockers (%)	45.1
(iv) Calcium channel blockers (%)	33.9
(v) Statins (%)	45.5
(vi) Antiarrhythmic drugs (%)	34.2

#Data are expressed as median and interquartile range.
sCD40L: soluble CD40 ligand, TIA: transient ischemic attack, MI: myocardial infarction, ACE: angiotensin converting enzyme, and ARBs: angiotensin receptor blockers.